CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 40 enrolled
Drug / intervention
Risperidone Long-Acting Injectable (RLAI)drug
Likely dose
Risperidone Long-Acting Injectable (RLAI) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00269919
NCT00269919Phase 4Completed
CompareCT.gov

Effect on Efficacy, Safety and Quality of Life by Long-Term Treatment of Long-Acting Risperidone Microspheres in Patients With Schizophrenia

Janssen Korea, Ltd., Korea·interventional·Posted Dec 26, 2005·Updated Apr 16, 2014

In Brief

A Phase 4 clinical trial evaluating Risperidone Long-Acting Injectable (RLAI) for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the long-term efficacy and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) and its influence on quality of life, in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 26, 2005
Enrollment StartAug 1, 2005
Primary CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.5 years ago

Interventions

Risperidone Long-Acting Injectable (RLAI)drug

The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.